Impact of Postoperative Therapy on Survival Outcomes in Non-small Cell Lung Cancer Patients With Microscopic Residual Disease.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17506

Hiroki Watanabe, Shota Nakamura, Yoshito Imamura, Shoji Okado, Yuji Nomata, Yuta Kawasumi, Yuka Kadomatsu, Harushi Ueno, Taketo Kato, Tetsuya Mizuno, Toyofumi Fengshi Chen-Yoshikawa

{"title":"Impact of Postoperative Therapy on Survival Outcomes in Non-small Cell Lung Cancer Patients With Microscopic Residual Disease.","authors":"Hiroki Watanabe, Shota Nakamura, Yoshito Imamura, Shoji Okado, Yuji Nomata, Yuta Kawasumi, Yuka Kadomatsu, Harushi Ueno, Taketo Kato, Tetsuya Mizuno, Toyofumi Fengshi Chen-Yoshikawa","doi":"10.21873/anticanres.17506","DOIUrl":null,"url":null,"abstract":"Background/aim: The aim of the study was to describe the specific characteristics of patients with microscopic residual disease (R1) after surgical resection for non-small cell lung cancer and to evaluate the effect of postoperative therapy in R1 patients.Patients and methods: We retrospectively reviewed the clinical data of 3,296 patients. Enrolled R1 patients were divided into two groups: those who received postoperative therapy (PT) and those who did not receive postoperative therapy (NPT).Results: A total of 52 R1 patients were enrolled. Of those, 27 (51.9%) underwent extended resections in addition to the standard surgery, 37 patients were assigned to the PT group and 15 to the NPT group. The PT group exhibited significantly longer overall survival (OS) than the NPT group (p<0.01, 5-year OS rate: 62.7% vs. 17.9%). There was no difference in progression-free survival (PFS) between the two groups (p=0.34, 5-year PFS rate: 38.7% vs. 22.2%). Age (<70 years old) and postoperative therapy positively impacted OS (p=0.03, and p=0.01, respectively).Conclusion: R1 resection after surgical resection for non-small cell lung cancer was more likely to occur in the patients receiving extended surgical resection. The PT group demonstrated a significantly better prognosis than the NPT group.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1193-1204"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17506","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The aim of the study was to describe the specific characteristics of patients with microscopic residual disease (R1) after surgical resection for non-small cell lung cancer and to evaluate the effect of postoperative therapy in R1 patients.

Patients and methods: We retrospectively reviewed the clinical data of 3,296 patients. Enrolled R1 patients were divided into two groups: those who received postoperative therapy (PT) and those who did not receive postoperative therapy (NPT).

Results: A total of 52 R1 patients were enrolled. Of those, 27 (51.9%) underwent extended resections in addition to the standard surgery, 37 patients were assigned to the PT group and 15 to the NPT group. The PT group exhibited significantly longer overall survival (OS) than the NPT group (p<0.01, 5-year OS rate: 62.7% vs. 17.9%). There was no difference in progression-free survival (PFS) between the two groups (p=0.34, 5-year PFS rate: 38.7% vs. 22.2%). Age (<70 years old) and postoperative therapy positively impacted OS (p=0.03, and p=0.01, respectively).

Conclusion: R1 resection after surgical resection for non-small cell lung cancer was more likely to occur in the patients receiving extended surgical resection. The PT group demonstrated a significantly better prognosis than the NPT group.

查看原文本刊更多论文

非小细胞肺癌显微残留病变患者术后治疗对生存结果的影响

背景/目的：本研究的目的是描述非小细胞肺癌手术切除后显微残留病变（R1）患者的具体特征，并评价R1患者术后治疗的效果。患者和方法：我们回顾性分析了3296例患者的临床资料。纳入的R1例患者分为两组：接受术后治疗（PT）组和未接受术后治疗（NPT）组。结果：共入组52例R1患者。其中，27例（51.9%）患者在标准手术的基础上进行了扩展切除，37例患者被分配到PT组，15例患者被分配到NPT组。PT组总生存期（OS）明显长于NPT组（pv）。17.9%)。两组无进展生存期（PFS）无差异（p=0.34, 5年PFS率：38.7%对22.2%）。年龄（p=0.03, p=0.01）。结论：非小细胞肺癌手术切除后R1切除在接受扩大手术切除的患者中更容易发生。PT组预后明显优于NPT组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.